Roche mulling GBP 8.7bn hostile bid for BioMarin Pharmaceuticals; AstraZeneca and Shire also interested
Roche, a listed Swiss pharmaceuticals company, was said to be mulling a potential GBP 8.7bn (EUR 10.44bn) hostile bid for BioMarin Pharmaceuticals, the Daily Express reported. The newspaper’s market report section cited market sources for speculation that Roche might table a hostile offer for BioMarin as early as next week.
The article also mentioned chatter that listed rivals AstraZeneca and Shire might follow suit with offers for BioMarin.
A market report in The Independent also mentioned talk that Roche might make an offer for BioMarin, adding that Shire and AstraZeneca are also said to be interested. The item did not cite a source for the rumour.
BioMarin’s market capitalisation currently stands at USD 8.43bn (EUR 6.28bn).
Source Daily Express, Independent